MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH

aka MJFF   |   New York, NY   |  http://www.michaeljfox.org

Mission

The Michael J. Fox Foundation was launched in 2000 and directs funds to promising research opportunities worldwide. The Foundation strives to make every dollar count as it seeks a cure for Parkinson's disease. With growing resources, the Foundation's focus is increasingly on the clinical and translational research crucial to making strides toward a cure and improved therapies for those living with Parkinson's today. Michael J. Fox was diagnosed with young-onset Parkinson's disease in 1991. Armed with the knowledge that with proper funding, a cure for Parkinson's disease was within reach, Fox publicly disclosed his condition in 1998 and committed himself to the campaign for increased Parkinson's awareness and research funding.

Ruling year info

2000

Chief Executive Officer and Co-Founder

Deborah W. Brooks

Main address

Grand Central Station PO Box 4777

New York, NY 10163 USA

Show more contact info

EIN

13-4141945

NTEE code info

Fund Raising and/or Fund Distribution (H12)

Specifically Named Diseases Research (H80)

Brain Disorders (H48)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

Parkinson’s disease (PD) affects nearly 1 million people in the United States and more than 6 million people worldwide, a figure estimated to double by 2040 as the population ages and becomes at increasing risk for neurologic disorders. PD occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die. Parkinson’s is a “movement disorder” and can result in symptoms of tremor, slowness, stiffness, walking and balance problems, as well as mood disorders and cognitive impairment. PD is a lifelong and progressive disease, which means that symptoms slowly worsen over time. There is no known cure and the need for new Parkinson’s treatments has never been more critical. The Michael J. Fox Foundation for Parkinson’s Disease works tirelessly every day with one urgent goal in mind: to find a cure for Parkinson’s and close our doors.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Funding for Parkinson's Disease Research

The Michael J. Fox Foundation for Parkinson's Research remains focused on funding innovative partnerships and programs that can move promising research to clinical application. The Foundation implements its research strategy through a diverse portfolio that includes: investigator-initiated programs, directive programs and collaborations. Investigator-Initiated Programs: The Foundation has designed programs to capture "best-in-field" Parkinson's research opportunities, inviting scientists from around the world to submit their best ideas across a range of disciplines with an emphasis on new and novel approaches. These investigator-initiated programs such as the Foundation's annual Fast Track program, allow the Foundation to keep an ear to the ground for the most innovative and promising ideas worldwide and attracts talented newcomers to the field. Directive Programs: The Michael J. Fox Foundation for Parkinson's Research and its Scientific Advisory Board has initiated a series of strategic scientific workshops to identify specific areas where the Foundation could dramatically advance the science. Each workshop focuses on a high priority area of Parkinson's research, bringing together leaders in the field to assess progress, examine constraints and recommend specific courses of action. In direct response to recommendations from these workshops the Foundation has been able to zero-in on, and fund, potentially high-impact areas of research with the goal of moving promising research to clinical application. Collaborations: The Foundation's scientific advisors have encouraged the Foundation to increase collaboration among researchers by funding innovative partnerships and programs. A notable example is LEAPS (Linked Efforts to Accelerate Parkinson's Solutions), a milestone-driven program designed to enable all-star research teams to jump-start progress through collaborative, multidisciplinary research efforts that address questions that will have meaningful impact on those living with Parkinson?s. In another collaborative effort, The Edmond J. Safra Global Genetics Consortia, participating researchers are required to share findings to improve understanding of genetics and Parkinson's.

Population(s) Served
Adults

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Total New Funding Deployed to speeding Parkinson's Disease Drug Development by Year (Program Expense Total)

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Related Program

Funding for Parkinson's Disease Research

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Numbers reflect USD

Number of New Research Grants Funded by Year (US and Non-US)

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Founded in 2000, The Michael J. Fox Foundation (MJFF) is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and ensuring the development of improved therapies for those living with Parkinson's.

From inception, MJFF has worked to jolt Parkinson’s drug development out of a standstill. Our activities go beyond funding basic research discoveries. We identify and fund innovative ideas in PD discovery (vetting over 600 Parkinson’s drug targets and supporting more than 125 clinical trials to date), including high-risk, high-reward opportunities; an approach that in less than two decades has transformed the broader approach in the Parkinson’s research field. We laser-focus on the drug targets that show real potential to help people, and proactively chaperone them along the complicated pipeline toward clinical trials. At the same time, the Foundation puts building blocks in place to increase the odds of clear, actionable results from those trials.

To get just one new drug from the lab to pharmacy shelves can take decades, billions of dollars and thousands of research volunteers. MJFF’s on-staff research team prioritizes research projects, gains stakeholder buy-in, and provides funding and technical assistance to push them forward. Our expertise in science and the business of science helps us solve systemic challenges standing in the way of progress and lets us target resources where they are needed most — to pay off for patients faster. We:

• Review nearly 1,000 grant proposals annually and fund millions in grants globally.

• Assemble Parkinson’s researchers worldwide to participate in our consortia, assess and review grants, and make use of our open-access data and research tools.

• Sponsor game changing, landmark clinical PD studies that offer open-access data for the wider research community.

• Mobilize patients and families to get involved in research, and develop platforms that provide accessible entry points.

Critical investments are made possible by the urgent optimism and actions of a passionate Parkinson’s community. In 2019, nearly 100,000 donors generously contributed to our mission, helping fund over $90 million in research programs; $10 million of which came from 5,800 Team Fox members who make up MJFF’s grassroots fundraising community.

MJFF works hard to maximize every dollar to drive science with the greatest potential to benefit people with PD. Since inception, 88 cents of every dollar we spend goes direct to high-impact research programs — with more than $1 billion in total research funded to date. We hold no endowment or excess financial reserves, deploying funds as quickly as possible for immediate impact.

Our in-house team of formally trained PhD and MD neuroscientists and project managers work closely with peer reviewers to make funding decisions, direct research goals and troubleshoot issues. Today, this team oversees a research portfolio of approximately 700 active grants.

MJFF’s world-class research program is focused on chaperoning promising ideas from whatever step they are in to the next step and ultimately to the investors who can get them to patients.

Multiple experimental treatments selected for early on support by MJFF have garnered significant follow-on funding and moved to the later stages of research (including clinical testing). Today, multiple therapies are in Phase III testing or filing for FDA approval. Research into disease-modifying therapies - that can delay, prevent or reverse PD - is a top priority for MJFF.

We are deepening our impact in the field as a leading convener. Representing patients at every turn, we understand the research process and are a partner to drug developers and trial sponsors. To move us all closer to the goal line, we continue to spearhead pre-competitive consortia to advance research, amplify the patient voice, and lead conversations with regulators to outline paths for therapeutic assessment.

Financials

MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH

Board of directors
as of 10/8/2021
SOURCE: Self-reported by organization
Board chair

Skip Irving

Douglas Ostrover

Barry Cohen

Elysium Management

Holly Andersen

The Ronald O. Perelman Heart Institute at The New York Presbyterian Hospital

Jon Brooks

JMB Capital Partners

Michael J. Fox

No Affiliation

Frederick Rowe

Rowe & Companies and Greenbrier Partners, Ltd.

Tracy Pollan

Actress

Nelle Fortenberry

Television Producer

Lily Safra

Edmond J. Safra Philanthropic Foundation

David Einhorn

Greenlight Capital

David Golub

No Affiliation

Fred Weiss

FGW Associates

Karen Finerman

Metropolitan Capital Advisors, Inc.

Curtis Schenker

Scoggin Capital Management

Donny Deutsch

Deutsch Inc.

Woody Shackleton

No Affiliation

Mark Booth

MTV Europe

Mark Hart

Corriente Advisors, LLC

Skip Irving

Edward Kalikow

The Kalikow Group

Marc Lipschultz

Kohlberg Kravis Roberts & Co.

Ryan Reynolds

Actor

George "Sonny" Whelen

Whelen Engineering Corp.

Akbar Gbajabiamila

NBC

Amar Kuchinad

ElectroniFIE Inc.

Andrew Creighton

VICE Media

Andy O'Brien

J.P. Morgan

Anne Holloway

American States Water Company

Anne-Cecilie Speyer

Never Stop Learning

Bonnie Strauss

Bachman-Strauss Foundation

Carolyn Schenker

The Hirschhorn Foundation

David Glickman

Ultra Mobile & Primo Connect

George Stephanopoulos

ABC

Glen Batchelder

John Daly

Goldman Sachs

Lee Fixel

Tiger Global Management

Ofer Nemirovsky

HarbourVest Partners

Peter Zaffino

AIG

Richard Schnall

Clayton, Dubilier, & Rice, LLC

Rick Tigner

Jackson Family Wines

Willie Geist

NBC, MSNBC

Keefer Jeffrey

Dupont Company

Hartley Richardson

James Richardson & Sons, Limited

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? Not applicable

Organizational demographics

SOURCE: Self-reported; last updated 08/10/2021

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Female, Not transgender (cisgender)
Sexual orientation
Heterosexual or Straight
Disability status
Person without a disability

Race & ethnicity

No data

Gender identity

No data

 

No data

Sexual orientation

No data

Disability

No data